Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Titan Pharma (TTNP)

Titan Pharma (TTNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Titan Pharma 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 USA

P: 650-244-4990 F: 650-244-4956

Description:

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Key Statistics

Overview:

Market Capitalization, $K 22,236
Enterprise Value, $K 15,906
Shares Outstanding, K 14,629
Annual Sales, $ 1,530 K
Annual Net Income, $ -8,780 K
Last Quarter Sales, $ 150 K
Last Quarter Net Income, $ -2,460 K
60-Month Beta 1.19
% of Insider Shareholders 2.70%
% of Institutional Shareholders 18.86%
Float, K 14,234
% Float 97.30%
Short Volume Ratio 0.47

Growth:

1-Year Return -29.52%
3-Year Return -87.80%
5-Year Return -99.47%
5-Year Revenue Growth -89.85%
5-Year Earnings Growth -100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 11/15/21
Next Earnings Date 08/22/22
Earnings Per Share ttm -0.19
EPS Growth vs. Prev Qtr 20.83%
EPS Growth vs. Prev Year 87.35%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payable Date 03/01/12
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 12/01/20

TTNP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -144.48%
Return-on-Assets % -104.30%
Profit Margin % -573.86
Net Margin % -203.09
Debt/Equity 0.00
Price/Sales 15.15
Price/Cash Flow N/A
Price/Book 3.36
Book Value/Share 0.47
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar